MSI-H/dMMR + PD-L1 expression	Neuroendocrine Tumor	MSI-H/dMMR + PD-L1 expression	Neuroendocrine Tumor	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
MSI-H/dMMR + PD-L1 expression	Triple Negative Breast Cancer	MSI-H/dMMR + PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Resistant: C4 – Case Studies atezolizumab Resistant : C4	atezolizumab Resistant: C4 – Case Studies atezolizumab Resistant : C4
MSI-H/dMMR + PD-L1 expression	Triple Negative Breast Cancer	MSI-H/dMMR + PD-L1 expression	Triple Negative Breast Cancer	sacituzumab govitecan-hziy Resistant: C4 – Case Studies sacituzumab govitecan-hziy Resistant : C4	sacituzumab govitecan-hziy Resistant: C4 – Case Studies sacituzumab govitecan-hziy Resistant : C4
MSI-H/dMMR + PD-L1 expression	Cholangiocarcinoma	MSI-H/dMMR + PD-L1 expression	Cholangiocarcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4

MSI-H/dMMR + PD-L1 expression

Associations